CADTH Horizon Scan

Tirzepatide for Type 2 Diabetes Mellitus
Authors: Matthew McDonald, Kelly Farrah

Acknowledgement: Baiju Shah, MD PhD FRCPC, Associate Professor, Department of Medicine, University of Toronto

ISSN: 2563-6596

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up to date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to Requests@CADTH.ca
# Table of Contents

**Key Messages** ........................................................................................................... 5

**Methods** ...................................................................................................................... 5

- Literature Search Strategy .......................................................................................... 5
- Study Selection ............................................................................................................. 6
- Peer Review ................................................................................................................ 6

**Background** ................................................................................................................. 6

**The Technology** .......................................................................................................... 7

**Regulatory Status** ...................................................................................................... 7

**Cost and Administration** .......................................................................................... 7

**Target Population** ...................................................................................................... 8

**Current Practice** ......................................................................................................... 8

**Summary of the Evidence** ........................................................................................ 8

- SURPASS-1 ................................................................................................................ 9
- SURPASS-2 ................................................................................................................ 9
- SURPASS-3 ................................................................................................................. 12
- SURPASS-4 ................................................................................................................ 13
- SURPASS-5 ................................................................................................................ 14

**Concurrent Developments** ....................................................................................... 15

**Considerations for Future Uptake** .......................................................................... 15

- Cardiovascular Benefit ............................................................................................. 15
- Target Population ...................................................................................................... 17
- Cost ............................................................................................................................ 17

**References** ............................................................................................................... 18
List of Tables

Table 1: Characteristics of Completed Phase III Randomized Controlled Trials ................................................. 10
Table 2: Characteristics of Ongoing Phase III Randomized Clinical Trials............................................................... 16
Key Messages

- Horizon Scan reports provide brief summaries of information regarding new and emerging health technologies; Health Technology Update articles typically focus on a single device or intervention. These technologies are identified through the CADTH Horizon Scanning Service as topics of potential interest to health care decision-makers in Canada. This Horizon Scan summarizes the available information regarding an emerging technology, tirzepatide, for the treatment of hyperglycemia in adults with type 2 diabetes.

- Type 2 diabetes (T2D) is a metabolic disease where blood glucose concentrations cannot be maintained at a normal level (hyperglycemia). Several antihyperglycemia drugs are currently available for the treatment of T2D including metformin, insulin secretagogues (meglitinides, sulfonylureas), dipeptidyl peptidase-4 (DPP4) inhibitors, sodium glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like polypeptide-1 (GLP-1) receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, and slow/fast-acting insulin analogues. Despite the number of drugs currently available to mitigate hyperglycemia, a significant unmet need for new therapeutics still exists.

- Tirzepatide (LY3298176; Eli Lilly Inc.) is a first in class dual glucagon-like polypeptide-1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist currently under development to treat hyperglycemia and obesity in individuals with T2D.

- To date, phase III clinical trials have been completed and several other trials are in progress to determine the efficacy of tirzepatide to reduce hyperglycemia (SURPASS studies) and obesity (SURMOUNT-2 study) in adults with T2D.

- This Horizon Scan bulletin focuses on the glycemic effect of tirzepatide in T2D. In summary, tirzepatide demonstrates efficacy in reducing mean glycated hemoglobin (A1C) compared to placebo, semaglutide, insulin degludec, and insulin glargine. Studies investigating the possible effect of tirzepatide on cardiovascular outcomes are currently ongoing.

Methods

These bulletins are not systematic reviews and do not involve critical appraisal or include a detailed summary of study findings. Rather, they present an overview of the technology and available evidence. They are not intended to provide recommendations for or against a particular technology.

Literature Search Strategy

A limited literature search was conducted by an information specialist on key resources including MEDLINE, Embase, the Cochrane Database of Systematic Reviews, the International HTA Database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. Clinical trials registries were searched: the US National Institutes of Health's clinicaltrials.gov, WHO's International Clinical Trials Registry Platform (ICTRP) search portal, Health Canada's Clinical Trials Database, and the European Union Clinical Trials Register. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concept was tirzepatide. No filters were applied to limit the retrieval by study type.
Where possible, retrieval was limited to the human population. The search was not restricted by language or date of publication.

**Study Selection**

One author screened the literature search results and reviewed the full text of all potentially relevant studies. Studies were considered for inclusion if the intervention was tirzepatide, the clinical trials were in phase III of development, and the condition was T2D. Conference abstracts and grey literature were included when they provided additional information to that available in the published studies.

**Peer Review**

A draft version of this bulletin was reviewed by a clinical expert. The sponsor was also given the opportunity to comment on an earlier draft.

**Background**

Diabetes is a metabolic disease characterized by an inability to produce and efficiently utilize insulin. As a result, patients with diabetes have difficulty regulating the concentration of glucose in their blood and experience hyperglycemia (high blood glucose). Diabetes is primarily classified as type 1, type 2, or gestational diabetes. Approximately 3 million Canadians (8.1%) are living with diabetes, representing 1 in 10 Canadian adults. Every year approximately 201,000 Canadians are newly diagnosed with diabetes. It is estimated that 90% of Canadians with diabetes have type 2 diabetes (T2D). T2D is multifaceted and can be caused by several factors, including but not limited to poor diet, obesity, physical inactivity, genetics, and environmental factors.

Diagnosis and management of T2D are determined by repetitive measurements of blood glucose concentrations or the percentage of A1C and symptoms of hyperglycemia. A fasting plasma glucose measurement of at least 7 mmol/L, a plasma glucose of at least 11.1 mmol/L 2 hours following a glucose tolerance test, a random plasma glucose measurement of at least 11.1 mmol/L, or a A1C of at least 6.5% are diagnostic criteria of T2D. If left untreated, T2D can lead to various hyperglycemia-associated complications such as neuropathy, nephropathy, retinopathy, and cardiovascular disease. Consequently, patients with T2D are at a heightened risk for major adverse cardiovascular events (MACE) and may have decreased life expectancy.

Based on Diabetes Canada clinical practice guidelines, metformin is the first-line treatment option for T2D due to its cost-effectiveness and safety profile. Several next-line antidiabetic drugs are available based on individual patient characteristics such as the risk or presence of heart failure, atherosclerotic cardiovascular disease, or kidney disease. These drugs include insulin secretagogues (meglitinides, sulfonylureas), dipeptidyl peptidase-4 (DPP4) inhibitors, sodium glucose co transporter 2 (SGLT2) inhibitors, GLP-1 receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, and slow/fast-acting insulin analogues.

Common side effects of antihyperglycemia medications include nausea (metformin, GLP-1 receptor agonists), weight gain (meglitinides, sulfonylureas, thiazolidinediones, insulin), and hypoglycemia risk (meglitinides, sulfonylureas, insulin). GLP-1 receptor agonists and
SGLT2 inhibitors have been associated with weight loss and lower risks of hypoglycemia. Due to early concerns that certain antidiabetic drugs may increase cardiovascular disease, and the inherent cardiovascular risk associated with T2D, both the Federal Drug Agency (FDA) of the US and Health Canada issued guidance on the development of new antidiabetic drugs emphasizing long-term cardiovascular safety. Cardiovascular outcome trials have shown that newer glucose lowering medications, such as GLP-1 receptor agonist and SGLT2 inhibitors, may have advantages on not only glycemic control, but complications of T2D including weight gain and cardiovascular and renal diseases. Glycemic control is fundamental to diabetes management. However, even with available antihyperglycemia medications, Canadian’s with T2D are not achieving glycemic targets.

The Technology

Tirzepatide (LY3298176; Eli Lilly Inc.) is a dual GLP-1 receptor and GIP receptor agonist under development to improve blood glucose concentrations, obesity, and heart failure with preserved ejection fraction. This Horizon Scan bulletin focuses on the effect of tirzepatide on glycemia in T2D. GLP-1 signalling reduces blood glucose concentrations by increasing glucose-dependent insulin release, slowing gastric emptying, and inhibiting glucagon release. Similarly, GIP signalling enhances meal-time insulin secretion to reduce blood glucose. However, the secretion of both incretins is diminished in populations with T2D. GIP receptors are also found in the hypothalamus, which suggests a role of GIP in signalling satiety. The combination of both GLP-1 and GIP receptor agonism has been shown in early clinical trials to improve glycemia and reduce body weight to a greater extent than GLP-1 agonism alone.

Regulatory Status

Tirzepatide is currently under review at the European Medicines Agency (submitted October 28, 2021) and the US FDA (submitted October 27, 2021).

Cost and Administration

Cost information for tirzepatide is currently unavailable. Tirzepatide is administered as a weekly subcutaneous injection. Phase III trials investigated the efficacy of tirzepatide at 5 mg, 10 mg, and 15 mg dosages; however, it is unknown what dosages will receive regulatory approval.
Target Population

Tirzepatide is initially anticipated to be used as a mono or adjunctive therapy to improve glycemic control in patients with T2D.

Current Practice

Diabetes Canada released full clinical practice guidelines for the prevention and management of diabetes in 2018\(^4\) and provided an update on pharmacologic glycemic management of T2D in adults in 2020.\(^6\) Patients with T2D are a heterogenous population, making treatment regimens and glycemic targets (i.e., A1C) for T2D highly individualized and complex.\(^11\) Treatment focuses on limiting hyperglycemia-associated symptoms (metabolic decompensation, ketoacidosis, dehydration, fatigue, etc.) and mitigating long-term complications such as heart, kidney, and vascular diseases.

In adults, if the A1C is lower than or equal to 1.5% above an individual's glycemic target at diagnosis, behavioural interventions are initially emphasized (nutritional guidance, physical activity).\(^6\) If glycemic targets are not reached within 3 months, or A1C is at least 1.5% above their glycemic target, behavioural interventions are supplemented with antihyperglycemia pharmacotherapy.\(^6\) Metformin is the first-line of therapy for T2D when hyperglycemia-related symptoms are not present; however, when hyperglycemia-associated symptoms are present, insulin with or without metformin is recommended.\(^6\) If A1C is 1.5% above an individual's glycemic target at diagnosis, initiating metformin in combination with a second antihyperglycemic agent, such as DPP4 inhibitors, insulin secretagogues (meglitinides, sulfonylureas), thiazolidinediones, SGLT2 inhibitors, or GLP-1 receptor agonists is recommended. Choice of second-line antihyperglycemic medications by health-care providers balance many factors including hyperglycemia, risk of hypoglycemia, body weight, efficacy of antihyperglycemic drugs for reducing blood glucose and limiting diabetes complications, adherence, affordability, side effects, and patient preferences.\(^6\)

In adults with T2D that have established, or risk factors for, atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, GLP1 receptor agonist and SGLT2 inhibitors are recommended.\(^6\) In addition, insulin treatment may also be initiated in individuals not achieving glycemic targets. Several antihyperglycemia medications are available in combination forms. Throughout the course of T2D treatment, antihyperglycemic drugs are often added, adjusted, and delicately balanced to meet the individual needs of the patient with T2D.

Summary of the Evidence

The literature search identified a total of 10 phase III trials from the SURPASS trial program (Table 1). Five trials are now complete with published full-text articles (SURPASS 1 to 5).\(^13-21\) 3 trials are complete but with no available results (SURPASS-J-mono, -J-compo, -AP-combo).\(^22-24\) and 2 trials are ongoing (SURPASS-6, SURPASS-CVOT).\(^25,26\) Trials without data or in progress will be discussed in the Concurrent Developments section. Phase III trials
investigating tirzepatide for additional indications are also briefly discussed in the Concurrent Developments section.

**SURPASS-1**

The SURPASS-1 study\textsuperscript{13,27} was a multi-centre (4 countries, not including Canada) phase III, randomized, double-blind, placebo-controlled trial. Participants were 18 years of age or older with T2D (N = 478), naive to diabetes injectable therapies, had a BMI of at least 23 kg/m\(^2\), and had inadequate glycemic control with diet and exercise alone (A1C 7.0% to 9.5%) at screening. Patients with T1D, history of pancreatitis, retinopathy, diabetic maculopathy, non-proliferative diabetic retinopathy requiring treatment, estimated glomerular filtration rate lower than or equal to 30 mL/min per 1.73 m\(^2\), or have used any oral antihyperglycemia medication for 3 months before screen were not included in the study. Baseline participant characteristics were similar between experimental groups. Across all trial participants the mean age of participants was 54.1 years of age, time since T2D diagnosis was 4.7 years, A1C 7.94%, BMI 31.9 kg/m\(^2\), and 54% of participants had not previously received oral hyperglycemic medications. After a 3-week screening period, participants were randomly assigned (1:1:1:1) to receive subcutaneous injections of tirzepatide (5 mg, 10 mg, or 15 mg) once weekly or placebo for 40 weeks. To reduce gastrointestinal tolerability, tirzepatide dosing was increased at 2.5 mg increments every 4 weeks until the maintenance dose was achieved. The primary outcome measure was the mean change in A1C from baseline at 40 weeks (reported here as efficacy estimand) and participants were monitored an additional 4 weeks to assess safety.

Tirzepatide reduced A1C across all 3 doses from baseline at 40 weeks. Compared to baseline, A1C decreased by a mean of −1.87% (standard error [SE] 0.09) with 5 mg tirzepatide (P < 0.0001), −1.89% (SE 0.10) with 10 mg tirzepatide (P < 0.0001), and −2.07% (SE 0.10) with 15 mg tirzepatide (P < 0.0001), compared to + 0.04% (SE 0.11) with placebo (P = 0.72). A higher proportion of participants receiving tirzepatide reached a target A1C of less than 7.0% (87% to 92% tirzepatide participants versus 19% placebo), a A1C of less than 6.5% (81% to 86% tirzepatide participants versus 10% placebo) or an A1C of less than 5.7% (31% to 52% tirzepatide participants versus 1% placebo).

A total of 11 serious adverse events were identified throughout the trial; 5 (4%) in participants that received 5 mg tirzepatide, 2 (2%) in participants that received 10 mg tirzepatide, 1 (1%) in participants that received 15 mg tirzepatide, versus 3 (3%) with placebo. No deaths were reported in participants that received tirzepatide and the most frequent adverse events were gastrointestinal. Nausea was reported in 14 (12%), 16 (13%), 22 (18%) participants receiving 5, 10, and 15 mg of tirzepatide, respectively, versus 7 (6%) in placebo. Diarrhea was reported in 14 (12%), 17 (14%), 14 (12%) participants receiving 5, 10, and 15 mg of tirzepatide, respectively, versus 9 (8%) in placebo. Hypoglycemia (< 4 mmol/L) was reported in 7 (6%) participants that received 5 mg tirzepatide, in 8 (7%) in participants that received 10 mg of tirzepatide. and in 8 (7%) in participants that received 15 mg of tirzepatide, compared to 1 (1%) in the placebo group. Severe hypoglycemia (< 3 mmol/L) was not reported in any tirzepatide participants.

**SURPASS-2**

The SURPASS-2 study\textsuperscript{19,28} was a multi-centre (8 countries, including Canada) phase III, open-label, randomized controlled trial that compared the efficacy and safety of tirzepatide versus semaglutide, a selective GLP-1 agonist. Participants were 18 years of age or older with T2D (N = 1,878), had inadequate glycemic control with metformin (1,500 mg/day), A1C
Table 1: Characteristics of Completed Phase III Randomized Controlled Trials

<table>
<thead>
<tr>
<th>Author, year, Name of study, NCT number</th>
<th>Study design, Study duration, Sample size</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator(s)</th>
<th>Primary outcome(s)</th>
</tr>
</thead>
</table>
| Rosenstock et al. 2021<sup>13</sup>  
SURPASS-1 (NCT03954834) | Double-blind, placebo controlled 40 weeks N = 478 | T2D (≥ 18 years old) Naive to diabetes injectable therapies  
≥ 3 months since taking OAM  
≥ 3 months stable body weight  
A1C 7.0% to 9.5%  
BMI ≥ 23 kg/m<sup>2</sup> | 5 mg tirzepatide weekly SC (n = 121)  
10 mg tirzepatide weekly SC (n = 121)  
15 mg tirzepatide weekly SC (n = 121) | Placebo SC (n = 115) | Mean change in A1C from baseline |
| Frías et al. 2021<sup>19</sup>  
SURPASS-2 (NCT03987919) | Open label 40 weeks N = 1,878 | T2D  
A1C 7.0% to 10.5%  
≥ 3 months stable metformin treatment (≥ 1,500 mg/day)  
≥ 3 months stable body weight  
BMI ≥ 25 kg/m<sup>2</sup> | 5 mg tirzepatide weekly SC (n = 470)  
10 mg tirzepatide weekly SC (n = 469)  
15 mg tirzepatide weekly SC (n = 470) | Semaglutide weekly SC (n = 469) | Mean change in A1C from baseline |
| Ludvik et al. 2021<sup>20</sup>  
SURPASS-3 (NCT03882970) | Open label 52 weeks N = 1,444 | T2D  
Insulin naive  
A1C 7.0% to 10.5%  
≥ 3 months stable metformin (≥ 1,500 mg/day) or metformin plus SGLT-2 inhibitor treatment  
≥ 3 months stable body weight  
BMI ≥ 25 kg/m<sup>2</sup> | 5 mg tirzepatide weekly SC (n = 358)  
10 mg tirzepatide weekly SC (n = 360)  
15 mg tirzepatide weekly SC (n = 359) | Insulin degludec daily SC (n = 360) | Mean change in A1C from baseline |
between 7.0% to 10.5%, BMI of at least 25 kg/m^2, and had stable weight (± 5%) the previous 3 months. Patients with T1D, estimated glomerular filtration rate at least 45 mL/min per 1.73 m^2, history of pancreatitis, non-proliferative diabetic retinopathy that required urgent treatment, proliferative diabetic neuropathy, or diabetic maculopathy were not included in the study. The mean age of participants was 56.6 years of age, time since T2D diagnosis was 8.6 years, A1C 8.28%, and a BMI 34.2 kg/m^2. Participants were randomly assigned (1:1:1:1) to receive subcutaneous injections of tirzepatide (5 mg, 10 mg, or 15 mg; doses were double-blind) once weekly or semaglutide (1 mg) for 40 weeks. Tirzepatide dosing was increased at 2.5 mg increments every 4 weeks until the maintenance dose was achieved. Beginning at a dose of 0.25 mg, semaglutide dosing was doubled weekly until 1 mg was reached at week 4. The primary outcome measure was the mean change in A1C from baseline at 40 weeks (reported here as efficacy estimand) and participants were monitored an additional 4 weeks to assess safety.

Compared to baseline, at 40 weeks tirzepatide reduced mean A1C by 2.09% (SEM 0.05) at 5 mg (P < 0.001), 2.37% (SEM 0.05) at 10 mg (P < 0.001), and 2.46% (SEM 0.05) at 15 mg
All 3 doses of tirzepatide reduced A1C to a greater extent than semaglutide; estimated treatment differences of −0.15 percentage points for 5 mg tirzepatide (95% confidence interval [CI], −0.28 to −0.03; P = 0.02), −0.39 percentage points for 10 mg tirzepatide (95% CI, −0.51 to −0.26; P < 0.001), −0.45 percentage points for 15 mg tirzepatide (95% CI, −0.57 to −0.32; P < 0.001). A higher proportion of participants receiving tirzepatide reached a target A1C of less than 7.0% (82% to 86% tirzepatide participants versus 79% semaglutide), an A1C less than 6.5% (69% to 80% tirzepatide participants versus 64% semaglutide) or an A1C of less than 5.7% (27% to 46% tirzepatide participants versus 19% semaglutide).

A total of 98 serious adverse events were identified throughout the study, with more occurring in tirzepatide participants than semaglutide; 33 (7%) in participants that received 5 mg tirzepatide, 25 (5.3%) in participants that received 10 mg tirzepatide, 27 (5.7%) in participants that received 15 mg tirzepatide, versus 13 (2.8%) in semaglutide. A total of 13 deaths (0.7%) occurred in the trial population (tirzepatide, n = 4 [0.9%] in each treatment arm and semaglutide, n = 1 [0.2%]). The most frequent reported adverse events were gastrointestinal, including but not limited to nausea (17% to 22% tirzepatide versus 18% semaglutide), diarrhea (13% to 16% tirzepatide versus 12% semaglutide), and vomiting (6% to 10% tirzepatide versus 8% semaglutide). Hypoglycemia (< 3 mmol/L) was reported in 3 (0.6%) participants that received 5 mg tirzepatide, in 1 (0.2%) in participants that received 10 mg of tirzepatide, and in 8 (1.7%) in participants that received 15 mg of tirzepatide, compared to 2 (0.4%) who received semaglutide.

**SURPASS-3**

The SURPASS-3 study was a multi-centre (13 countries, not including Canada) phase III, open-label, randomized controlled trial that compared the efficacy of tirzepatide to insulin degludec, a long-acting basal insulin analogue. Patients were 18 years of age or older with T2D (N = 1,444), insulin naive, had inadequate glycemic control on a stable dose of metformin, with or without SGLT2 inhibitors for at least 3 months before screening. In addition, participants had an A1C between 7.0% to 10.5%, a BMI at least 25 kg/m², and stable weight (± 5%) for at least 3 months. Patients with T1D, history of pancreatitis, diabetic retinopathy or maculopathy, and an estimated glomerular filtration rate of lower than or equal to 45 mL/min per 1.73 m² were not included in the study. The mean age of participants was 57.4 years of age, time since T2D diagnosis was 8.4 years, A1C 8.17%, and a BMI 33.5 kg/m². The majority of participants in the SURPASS-3 study were white (91%). Participants were randomly assigned (1:1:1:1) to receive a subcutaneous injection of tirzepatide (5 mg, 10 mg, or 15 mg) weekly or insulin degludec daily for 52 weeks. Tirzepatide dosing was increased at 2.5 mg increments every 4 weeks until the maintenance dose was achieved. Insulin degludec was administered with a prefilled pen containing 3 mL (U100/mL) daily, titrating weekly starting with 10 U per day. The primary outcome measure was mean change in A1C from baseline at 52 weeks (reported here as efficacy estimand) and participants were monitored an additional 4 weeks to assess safety.

At 52 weeks, compared to baseline, mean A1C decreased by −1.93% (SE 0.05) with 5 mg tirzepatide, −2.20% (SE 0.05) with 10 mg tirzepatide, and −2.37% (SE 0.05) with 15 mg tirzepatide, compared to −1.34% (SE 0.05) with insulin degludec. Estimated treatment differences versus insulin degludec was −0.59 percentage points for 5 mg tirzepatide (95% confidence interval [CI], −0.73 to −0.45; P < 0.0001), −0.86 percentage points for 10 mg tirzepatide (95% CI, −1.00 to −0.72; P < 0.0001), −1.04 percentage points for 15 mg tirzepatide (95% CI, −1.17 to −0.90; P < 0.0001). A higher proportion of participants receiving tirzepatide
reached a target A1C of less than 7.0% (82% to 93% tirzepatide participants versus 61% insulin degludec), an A1C of less than 6.5% (71% to 85% tirzepatide participants versus 44% insulin degludec) or an A1C of less than 5.7% (26% to 48% tirzepatide participants versus 5% insulin degludec).

A total of 97 serious adverse events were identified throughout the study, which were evenly distributed between tirzepatide and insulin degludec treated participants; 29 (8%) in participants that received 5 mg tirzepatide, 20 (6%) in participants that received 10 mg tirzepatide, 26 (7%) in participants that received 15 mg tirzepatide, versus 22 (6%) in insulin degludec. A total of 5 deaths (0.3%) occurred in the trial population and were evenly distributed across participants. The most frequent reported adverse events were gastrointestinal and occurred to a greater extent in tirzepatide treated participants. Gastrointestinal symptoms were primarily nausea (12% to 24% tirzepatide versus 2% insulin degludec), diarrhea (15% to 17% with tirzepatide versus 4% with insulin degludec), decreased appetite (6% to 12% tirzepatide versus 1% insulin degludec), and vomiting (6% to 10% tirzepatide versus 1% insulin degludec). Hypoglycemia (< 3 mmol/L) was reported in 5 (1%) participants that received 5 mg tirzepatide, in 4 (1%) in participants that received 10 mg of tirzepatide, and in 7 (2%) in participants that received 15 mg of tirzepatide, compared to 26 (7%) who received insulin degludec.

SURPASS-4

The SURPASS-4 study\textsuperscript{18,30} was a multi-centre (14 countries, including Canada) phase III, open-label, randomized controlled trial that compared the efficacy of tirzepatide to insulin glargine, a long-acting basal insulin analogue. Patients were 18 years of age or older with T2D (N = 2,002), that had inadequate glycemic control with any combination of metformin, sulfonylurea, or SGLT-2 inhibitors. In addition, participants had an A1C between 7.5% to 10.5%, a BMI of at least 25 kg/m\textsuperscript{2}, stable weight (± 5%) for at least 3 months, and at increased risk of cardiovascular events. Cardiovascular risk was defined as coronary, peripheral arterial, or cerebrovascular disease, or 50 years of age or older with a history of chronic kidney disease (estimated glomerular filtration rate of lower than or equal to 60 mL/min per 1.73 m\textsuperscript{2}) or history of congestive heart failure. Across trial participants the mean age was 63.6 years of age, mean duration of diabetes was 11.8 years, A1C 8.52%, and a BMI 32.6 kg/m\textsuperscript{2}. Most trial participants were white (81.5%), with the remaining participants identifying as Asian (3.5%), Native Hawaiian, or other Pacific Islander (0.2%), Black/African American (3.8%), American Indian, or Alaska Native (8.7%), or more than 1 race (2.1%). Participants were randomly assigned (1:1:1:3) to receive a subcutaneous injection of tirzepatide (5 mg, 10 mg, or 15 mg) weekly or insulin glargine daily for 52 weeks. Tirzepatide dosing was increased at 2.5 mg increments every 4 weeks until the maintenance dose was achieved. Insulin glargine was administered with a prefilled pen containing 3 mL (U100/mL) daily, titrating weekly starting with 10 U per day. The primary outcome measure was mean change in A1C from baseline at 52 weeks (reported here as efficacy estimand) and participants were monitored an additional 4 weeks to assess safety.

At 52 weeks, compared to baseline, mean A1C decreased by −2.24% (SE 0.05) with 5 mg tirzepatide, −2.43% (SE 0.05) with 10 mg tirzepatide, and −2.58% (SE 0.05) with 15 mg tirzepatide, compared to −1.44% (SE 0.05) with insulin glargine. Estimated treatment differences versus insulin glargine was −0.80 percentage points for 5 mg tirzepatide (95% confidence interval [CI], −0.92 to −0.68; P < 0.0001), −0.99 percentage points for 10 mg tirzepatide (95% CI, −1.11 to −0.87; P < 0.0001), −1.14 percentage points for 15 mg tirzepatide (95% CI, −1.26 to −1.02; P < 0.0001). A higher proportion of participants receiving tirzepatide
reached a target A1C of less than 7.0% (81% to 91% tirzepatide participants versus 51% insulin glargine), an A1C of less than 6.5% (66% to 81% tirzepatide participants versus 32% insulin glargine) or an A1C of less than 5.7% (23% to 43% tirzepatide participants versus 3% insulin glargine).

A total of 336 serious adverse events were identified throughout the study; 48 (15%) in participants that received 5 mg tirzepatide, 54 (17%) in participants that received 10 mg tirzepatide, 41 (12%) in participants that received 15 mg tirzepatide, versus 193 (19%) in insulin glargine. A total of 60 deaths occurred in trial participants (tirzepatide, n = 25 [3%] and glargine, n = 35 [4%]) and no increased risk of major adverse cardiac events (MACE-4) for pooled tirzepatide versus glargine was identified (hazard ratio [HR 0.74], 95% CI, 0.51 to 1.08). The most frequent reported adverse events were gastrointestinal, including but not limited to nausea (12% to 23% tirzepatide versus 2% insulin glargine), diarrhea (13% to 22% tirzepatide versus 4% insulin glargine), vomiting (5% to 9% tirzepatide versus 2% insulin glargine), and loss of appetite (9% to 11% tirzepatide versus < 1% insulin glargine). Hypoglycemia (< 3 mmol/L) was reported in 29 (9%) participants that received 5 mg tirzepatide, in 20 (6%) in participants that received 10 mg of tirzepatide, and in 27 (8%) in participants that received 15 mg of tirzepatide, compared to 191 (19%) who received insulin glargine.

SURPASS-5
The SURPASS-5 study was a multi-centre (8 countries, not including Canada) phase III, randomized, double-blind, placebo-controlled trial that compared the efficacy of tirzepatide to placebo in patients with T2D that were already on insulin glargine, with or without metformin. Participants were 18 years of age or older with T2D (N = 475), treated with insulin glargine (U100), once daily with or without metformin for at least 3 months, had a BMI at least 23 kg/m², had inadequate glycemic control (A1C 7.0% to 10.5%) at screening, and stable weight (± 5%) for at least 3 months. Participants with pancreatitis, diabetic retinopathy or maculopathy, or an estimated glomerular filtration rate 30 mL/min or less per 1.73m² were not included in the study. Across trial participants the mean age was 60.6 years of age, A1C was 8.31%, and a BMI 33.4 kg/m². Most trial participants were white (80%), with the remaining participants identifying as Asian (17.9%), Black/African American (1.3%), American Indian or Alaska Native (0.4%), or more than 1 race (0.4%). Participants were randomly assigned (1:1:1:1) to receive a weekly subcutaneous injection of tirzepatide (5 mg, 10 mg, or 15 mg) weekly or placebo for 40 weeks. The primary outcome measure was mean change in A1C from baseline at 40 weeks (reported here as efficacy estimand) and participants were monitored an additional 4 weeks to assess safety.

Compared to baseline, A1C decreased by −2.23% (SE 0.08) with 5 mg tirzepatide, −2.59% (SE 0.08) with 10 mg tirzepatide, and −2.59% (SE 0.08) with 15 mg tirzepatide, compared to −0.93% (SE 0.08) with placebo. Estimated treatment differences versus placebo was −1.30 percentage points for 5 mg tirzepatide (95% confidence interval [CI], −1.52 to −1.07; P < 0.001), −1.66 percentage points for 10 mg tirzepatide (95% CI, −1.88 to −1.43; P < 0.001), −1.65 percentage points for 15 mg tirzepatide (95% CI, −1.88 to −1.43; P < 0.001). A higher proportion of participants receiving tirzepatide reached a target A1C of less than 7.0% (93% to 97% tirzepatide participants versus 34% placebo), an A1C of less than 6.5% (80% to 95% tirzepatide participants versus 17% placebo) or an A1C of less than 5.7% (26% to 62% tirzepatide participants versus 3% placebo).

Forty-one serious adverse events were identified throughout the study; 9 (8%) in participants that received 5 mg tirzepatide, 13 (11%) in participants that received 10 mg tirzepatide, 9
(8%) in participants that received 15 mg tirzepatide, versus 10 (8%) in insulin glargine. No deaths occurred in trial participants. The most common adverse events were gastrointestinal, including diarrhea (12% to 21% tirzepatide versus 10% placebo), nausea (13% to 18% tirzepatide versus 3% placebo), and vomiting (7% to 13% tirzepatide versus 3% placebo). Hypoglycemia (< 3 mmol/L) was reported in 18 (15.5%) participants that received 5 mg tirzepatide, in 23 (19.3%) in participants that received 10 mg of tirzepatide, and in 17 (14.2%) in participants that received 15 mg of tirzepatide, compared to 15 (12.5%) who received placebo.

**Concurrent Developments**

Phase III clinical trials without data available or currently in progress are summarized in Table 2. SURPASS J-mono\(^2\) is a trial determining the glycemic efficacy and safety of tirzepatide compared to dulaglutide, a GLP-1 analogue, in participants with T2D from Japan. SURPASS J-combo\(^3\) is a trial investigating the long-term safety of tirzepatide in combination with oral antihyperglycemic medications in patients with diabetes in Japan. SURPASS-AP-combo\(^4\) is a trial comparing the glycemic efficacy of tirzepatide to insulin glargine in participants with T2D on metformin with or without sulfonylurea. The ongoing SURPASS-6\(^5\) study is comparing the glycemic efficacy of tirzepatide once weekly versus insulin lispro (U100) 3 times daily in participants with T2D inadequately controlled on insulin glargine (U100) with or without metformin. To assess MACE, the SURPASS-CVOT\(^6\) study is assessing the efficacy and safety of tirzepatide to dulaglutide in participants with T2D and increased cardiovascular risk.

Concurrent with assessing the efficacy of tirzepatide at reducing A1C in T2D, tirzepatide is also being investigated for treating obesity in those with/without T2D (SURMOUNT\(^33-37\) studies) and heart failure (SUMMIT\(^38\) study).

**Considerations for Future Uptake**

**Cardiovascular Benefit**

T2D enhances the progression of cardiovascular diseases, leaving patients with T2D at a heightened risk for major adverse cardiovascular events (MACE).\(^4,9\) SURPASS-4\(^1\) evaluated the glycemic efficacy and cardiovascular safety of tirzepatide for 52 weeks compared to insulin glargine in participants with T2D at heightened risk of cardiovascular diseases. A meta-analysis of the SURPASS studies suggests that tirzepatide does not increase the risk of MACE in participants with T2D.\(^6\) However, trials assessing longer-term major averse cardiovascular events are still ongoing (SURPASS-CVOT\(^6\)). Based on available evidence,\(^4\) Diabetes Canada’s clinical practice guidelines for the prevention and management of diabetes already recommends some GLP-1 receptor agonists alone or SGLT2 inhibitors for longer-term cardio- and renal benefits.\(^6\) Pending the availability of longer-term data on cardiovascular outcomes and the completion of the SURPASS-CVOT study in 2024,\(^7\) uptake of tirzepatide for cardiovascular benefits may likely be limited.
### Table 2: Characteristics of Ongoing Phase III Randomized Clinical Trials

<table>
<thead>
<tr>
<th>Name of study, NCT number, study completion date</th>
<th>Study design, Study duration, Sample size</th>
<th>Population</th>
<th>Intervention(s)</th>
<th>Comparator(s)</th>
<th>Primary outcome(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SUPRASS J-mono</strong> (NCT03861052) Completion date: March 2021</td>
<td>Double blind, 52 weeks, N = 636</td>
<td>T2D</td>
<td>Interventions: 5 mg tirzepatide weekly SC, 10 mg tirzepatide weekly SC, 15 mg tirzepatide weekly SC</td>
<td>Comparator: Dulaglutide 0.75 mg</td>
<td>Mean change in A1C from baseline</td>
</tr>
<tr>
<td><strong>SUPRASS J-combo</strong> (NCT03861039) Completion date: February 2021</td>
<td>Open label, 52 weeks, N = 442</td>
<td>T2D</td>
<td>Interventions: 5 mg tirzepatide weekly SC, 10 mg tirzepatide weekly SC, 15 mg tirzepatide weekly SC</td>
<td>Comparator: Dulaglutide 0.75 mg</td>
<td>Number of patients with ≥ 1 SAE</td>
</tr>
<tr>
<td><strong>SUPPASS-AP combo</strong> (NCT04093752) Completion date: November 2021</td>
<td>Open label, 40 weeks, N = 917</td>
<td>T2D</td>
<td>Interventions: 5 mg tirzepatide weekly SC, 10 mg tirzepatide weekly SC, 15 mg tirzepatide weekly SC</td>
<td>Comparator: Insulin glargine</td>
<td>Mean change in A1C from baseline</td>
</tr>
</tbody>
</table>
Target Population

Ethnicity is a significant risk factor for T2D. Most SURPASS participants were white, with limited representation of minority populations. Indigenous peoples and communities of colour represent more than 20% of the Canadian population and have an increased prevalence of T2D. Although race may influence the cardiovascular efficacy of other drugs, such as SGLT-2 inhibitors and GLP-1 agonists, it is too early in clinical development to understand how the efficacy of tirzepatide might differ in different subpopulations.

SURPASS participants were on average 55 years of age and older. Although there is an increased frequency of T2D diagnosis occurring in children and adolescence, no data are available at this time for this age demographic.

Cost

The prevalence of T2D is increasing in Canada and newer drug classes to treat T2D contribute significantly to growth in public drug program spending in Canada. Although the price of tirzepatide is currently not available, future cost-effectiveness studies will be necessary to determine if tirzepatide adds value to the existing drug classes already available in Canada.

### Ongoing trials

<table>
<thead>
<tr>
<th>Name of study, NCT number, study completion date</th>
<th>Study design, Study duration, Sample size</th>
<th>Population</th>
<th>Intervention(s) Comparator(s)</th>
<th>Primary outcome(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SURPASS-6 (NCT04537923)</td>
<td>Open label 52 weeks N = 1,182</td>
<td>T2D A1C 7.5% to 11.0% ≥ 90 days treated with basal insulin with/without metformin, sulfonylureas, or DPP4 inhibitors ≥ 3 months stable body weight BMI ≥ 23 kg/m²</td>
<td>Interventions: 5 mg tirzepatide weekly SC 10 mg tirzepatide weekly SC 15 mg tirzepatide weekly SC Comparator: Insulin lispo</td>
<td>Mean change in A1C from baseline</td>
</tr>
<tr>
<td>Estimated completion date: October 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SURPASS-CVOT (NCT04255433)</td>
<td>Double blind Event driven N = 12,500</td>
<td>T2D Atherosclerotic cardiovascular disease A1C 7.0% to 10.5% BMI ≥ 25 kg/m²</td>
<td>Interventions: tirzepatide weekly SC Comparator: Dulaglutide</td>
<td>Time to first occurrence of a component of event of MACE-3 (cardiovascular death, myocardial infarction, or stroke)</td>
</tr>
<tr>
<td>Estimated completion date: October 2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A1C = glycated hemoglobin; BMI = body mass index; DPP4 = Dipeptidyl peptidase-4; MACE = major adverse cardiovascular event; OAM = oral antihyperglycemic medication; RCT = randomized controlled trials; SAE = severe adverse event; SGL T-2 = sodium glucose cotransporter; T2D = Type 2 diabetes.
References


44. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes. Diabetes Care. 2021;44(5):1236-1241. PubMed